Učitavanje...
The clinical utility of aflibercept for diabetic macular edema
The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest anti-VEGF drug, aflibercept, has recently been approved by the United States Food and Drug Administrat...
Spremljeno u:
Izdano u: | Diabetes Metab Syndr Obes |
---|---|
Glavni autor: | |
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
Dove Medical Press
2015
|
Teme: | |
Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4583120/ https://ncbi.nlm.nih.gov/pubmed/26425104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S72792 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|